Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Vuja De Sciences logo — Vuja De is dedicated to developing cancer metastasis treatme...

Vuja De Sciences

Vuja De is dedicated to developing cancer metastasis treatments that prevent cancer progression and recurrence.

Founded 2017 7 employees Series Unknown Biotechnology, Health Care +2

General Information

Company Name Vuja De Sciences
Founded Year 2017
Founders / Decision Makers
Team member
Employees 7
Industries Biotechnology, Health Care, Health and Wellness +1
Funding Stage Series Unknown
Social

Get notified when Vuja De Sciences moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Vuja De Sciences

Vuja De Sciences is a biotechnology startup that is focused on developing treatments for cancer metastasis, with the aim of preventing cancer progression and recurrence. The company's initial focus is on osteosarcoma, a rare bone cancer that predominantly affects adolescents, before expanding to other types of cancer. Vuja De Sciences employs advanced laboratory technologies for metastatic preclinical endpoints in combination with Comparative Oncology to minimize risk and optimize product development for successful human oncology clinical trials. The company is currently testing both repurposed drugs previously used in human clinical trials and novel preclinical drugs. In Comparative Oncology, canine patients with naturally occurring cancer are included in clinical trials, offering potential benefits for both humans and their furry companions. Importantly, dog osteosarcoma closely mirrors human osteosarcoma, making drugs effective in dogs highly relevant to human treatment. Additionally, the faster cancer progression in dogs is advantageous for cancer recurrence trials, as it allows for the acceleration of processes that may take years in humans. Founded in 2017, Vuja De Sciences operates in the industries of biotechnology, healthcare, health and wellness, and life sciences. The company received its most recent investment, a Venture - Series Unknown round, on 28 May 2024. The specific investors involved in this funding round have not been disclosed.

Taxonomy: Cancer Metastasis Treatments, Preventing Cancer Progression, Recurrence Prevention, Osteosarcoma Treatment, Comparative Oncology, Metastatic Preclinical Endpoints, Drug Repurposing, Novel Preclinical Drugs, Canine Clinical Trials, Maintenance Therapy, Adjuvant Therapy, Phenotypic Screening, Pediatric Cancer, Drug Screening

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Venture - Series Unknown •••••• - 28 May 2024
Venture - Series Unknown •••••• - 30 Oct 2023
Venture - Series Unknown •••••• - 29 Nov 2022
Debt Financing •••••• - 24 Apr 2019

Vuja De Sciences Alternatives & Competitors

Vuja De Sciences vs
Ectin Research
Ectin Research Sweden

Medicine not ´miracle´ MFA-370: a novel therapy eliminating cancer tumors.

Seed
1 employees
Vuja De Sciences vs
FidoCure®
FidoCure® United States

AI-enabled precision medicine platform for canine cancer: Fighting cancer on both ends of the leash....

Series Unknown
22 employees
Health Care
Vuja De Sciences vs
Lantern Pharma Inc. (Nasdaq: LTRN)
Lantern Pharma Inc. (Nasdaq: LTRN) United States

Leveraging Artificial Intelligence to Rescue and Develop Cancer Therapies

Post Ipo Secondary
28 employees
AI, Biopharma

FAQ About Vuja De Sciences

Vuja De is dedicated to developing cancer metastasis treatments that prevent cancer progression and recurrence.
Vuja De Sciences was founded in 2017.
Vuja De Sciences operates in the following industries: Biotechnology, Health Care, Health and Wellness, Life Sciences.
Vuja De Sciences has approximately 7 employees.
Vuja De Sciences has completed 4 funding rounds. The latest funding stage is Series Unknown.
Top alternatives and competitors to Vuja De Sciences include Ectin Research, FidoCure® , Lantern Pharma Inc. (Nasdaq: LTRN), Oncorena AB, Nilogen Oncosystems. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Vuja De Sciences and Ectin Research are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Vuja De Sciences and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy